| 2.34 0 (0%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.07  |
1-year : | 3.31 |
| Resists | First : | 2.62 |
Second : | 2.83 |
| Pivot price | 2.6 |
|||
| Supports | First : | 2.28 |
Second : | 1.9 |
| MAs | MA(5) : | 2.42 |
MA(20) : | 2.6 |
| MA(100) : | 2.56 |
MA(250) : | 2.67 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 4.1 |
| RSI | RSI(14): 38 | |||
| 52-week | High : | 7.32 | Low : | 2.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VERU ] has closed above bottom band by 5.3%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.38 | 2.38 - 2.39 |
| Low: | 2.26 - 2.27 | 2.27 - 2.29 |
| Close: | 2.31 - 2.34 | 2.34 - 2.36 |
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Mon, 17 Aug 2026
Veru (VERU) chief scientist adds 1,800 shares in open-market buy - stocktitan.net
Mon, 03 Aug 2026
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th - GlobeNewswire
Sun, 26 Jul 2026
Veru Inc. Revenue Breakdown – NASDAQ:VERU - TradingView
Thu, 11 Jun 2026
Why is Veru stock rising 10% today? - Investing.com
Fri, 05 Jun 2026
Veru And 2 Other Intriguing Penny Stocks To Watch - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 19.7 (%) |
| Shares Short | 1,400 (K) |
| Shares Short P.Month | 1,410 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.1 % |
| Return on Equity (ttm) | -64.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -3.84 |
| PEG Ratio | 3.5 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.54 |
| Dividend | 0.69 |
| Forward Dividend | 0 |
| Dividend Yield | 29.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|